PMID- 38450071
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240308
IS  - 1664-2295 (Print)
IS  - 1664-2295 (Electronic)
IS  - 1664-2295 (Linking)
VI  - 15
DP  - 2024
TI  - Case report: Resolution of Guillain-Barre syndrome in a patient with dual primary 
      tumors after treatment with rituximab.
PG  - 1348304
LID - 10.3389/fneur.2024.1348304 [doi]
LID - 1348304
AB  - Guillain-Barre syndrome (GBS) is a rare immune-related adverse event (irAE) that 
      can occur in solid tumors such as hepatocellular carcinoma, gastric cancer, 
      breast cancer, and colorectal cancer. It is characterized by progressive 
      myasthenia and mild sensory abnormalities. The emergence of immune checkpoint 
      inhibitors (ICIs) has significantly improved cancer patients' life expectancy but 
      can also trigger various irAEs, including GBS. We report a rare case of GBS in a 
      64-year-old male patient with dual primary tumors of the colon and stomach who 
      received toripalimab and chemotherapy for liver metastases. After five 
      treatments, the patient experienced weakness and numbness in his limbs. Lumbar 
      puncture, electromyography, and other tests confirmed the diagnosis of GBS. 
      Intravenous immunoglobulin (IVIG) and methylprednisolone did not improve the 
      patient's symptoms, but rituximab, which is not a standard regimen for GBS, was 
      effective in eliminating B cells and improving symptoms. Following this, we 
      effectively shifted from a regimen combining immunotherapy and chemotherapy to a 
      targeted therapy regimen, resulting in prolonged patient survival. Currently, 
      limited studies have been undertaken to evaluate the efficacy of rituximab in 
      managing refractory neurological adverse events associated with ICI therapy. 
      Using this case, we reviewed similar cases and formed our views.
CI  - Copyright (c) 2024 Zhang, Wang and Zhou.
FAU - Zhang, Desheng
AU  - Zhang D
AD  - Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan 
      University, Wuhan, China.
FAU - Wang, You
AU  - Wang Y
AD  - Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan 
      University, Wuhan, China.
FAU - Zhou, Fuxiang
AU  - Zhou F
AD  - Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan 
      University, Wuhan, China.
LA  - eng
PT  - Case Reports
DEP - 20240221
PL  - Switzerland
TA  - Front Neurol
JT  - Frontiers in neurology
JID - 101546899
PMC - PMC10915274
OTO - NOTNLM
OT  - Guillain-Barre syndrome
OT  - case report
OT  - immune checkpoint inhibitors
OT  - targeted therapy
OT  - tumor
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2024/03/07 06:43
MHDA- 2024/03/07 06:44
PMCR- 2024/02/21
CRDT- 2024/03/07 04:14
PHST- 2023/12/02 00:00 [received]
PHST- 2024/02/12 00:00 [accepted]
PHST- 2024/03/07 06:44 [medline]
PHST- 2024/03/07 06:43 [pubmed]
PHST- 2024/03/07 04:14 [entrez]
PHST- 2024/02/21 00:00 [pmc-release]
AID - 10.3389/fneur.2024.1348304 [doi]
PST - epublish
SO  - Front Neurol. 2024 Feb 21;15:1348304. doi: 10.3389/fneur.2024.1348304. 
      eCollection 2024.